Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas. - Wikidata - wikimedia - TriplyDB

Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas.

Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas.

http://www.wikidata.org/entity/Q33890039

about

Wnt5a Signaling in Cancer MALDI Imaging Mass Spectrometry (MALDI-IMS)-application of spatial proteomics for ovarian cancer classification and diagnosis.Wnt5a Signaling in Normal and Cancer Stem Cells Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans.WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway.Effect of targeted silencing of IL-8 on in vitro migration and invasion of SKOV3 ovarian cancer cells.Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer.Ovarian cancer molecular pathology.Prognostic role of serum AZGP1, PEDF and PRDX2 in colorectal cancer patients.

P2860

Q26738408-7147035B-0436-4524-9D13-6A30C01E451A Q30476935-869AA41B-3412-411C-BC7B-35E8E90D1CE4 Q33604792-235CD86A-64B7-4C1F-A8DE-2E667F82F33F Q35768137-4EB3FCD3-D66D-4803-9765-5C533F365354 Q35840116-2DE84017-2005-40EE-ABB5-D52F84584784 Q37701277-66D1E51C-7BFB-434F-BA9E-5EC40DF45156 Q37739177-F431E17C-1EC3-4BBA-9962-A806916F124A Q38021356-29B8EE3E-EBFE-4EED-8801-E9AB2E6ADBA4 Q53258352-F5265FD4-9183-48FE-BDDD-17F9D673047E

P2860

Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas.

http://www.wikidata.org/entity/Q33890039

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Comparative proteomic analysis ...... rioid ovarian adenocarcinomas.

@ast

Comparative proteomic analysis ...... rioid ovarian adenocarcinomas.

@en

type

label

Comparative proteomic analysis ...... rioid ovarian adenocarcinomas.

@ast

Comparative proteomic analysis ...... rioid ovarian adenocarcinomas.

@en

prefLabel

Comparative proteomic analysis ...... rioid ovarian adenocarcinomas.

@ast

Comparative proteomic analysis ...... rioid ovarian adenocarcinomas.

@en

P1433

Q33890039-144FCF9E-F5ED-4C72-B1E4-1CE866D68B08

P1476

Q33890039-8BA62AB9-7107-4BCA-BDA1-B968815EDB01

P2093

Q33890039-10B23A14-CE90-4DD3-9000-330370201F86

Q33890039-118DFE2D-BED0-4D88-ACF8-109DCBC6AA1F

Q33890039-375F3068-B991-4118-B89E-D78059F3E748

Q33890039-3E94FA21-CF9C-4098-8414-6D40B875D2FE

Q33890039-74AA061A-D7EC-4A2C-9DE2-E49653FCF9FD

Q33890039-D54635B6-35E2-4083-A7D2-1553891EFFD7

Q33890039-DF34A896-B189-4673-9D20-2FC926C2F37F

Q33890039-E6F561AD-B085-41F7-AF35-C8A17C239D8F

P2860

Q33890039-0472DF7F-92C0-4FF0-85D2-07C7D28E4610

Q33890039-07204C39-C067-4CA2-A41E-35FD5673E7BA

Q33890039-2E381FB1-6F51-4505-9104-105B0E95C086

Q33890039-2ED4D974-84CF-413B-9FC0-4C3196A74DB6

Q33890039-32AE944B-D509-4873-8B65-FD2B267F7136

Q33890039-3A3B9794-BB7C-4575-8123-AE89C0EB30C9

Q33890039-485AA94A-7364-48A5-BD50-24507EC9398C

Q33890039-4E32BF76-19D8-450B-B701-9768B0B44250

Q33890039-5B78F1C9-BAEE-4C79-99EA-03B2C0615D20

Q33890039-5CC7C82D-5302-4919-89F7-D07DC65C9C5C

P304

Q33890039-6975E2BD-E028-4326-A503-E50E9228B801

P31

Q33890039-7A4F2A2D-C4EA-432F-ABBE-E1062583CD8F

P356

Q33890039-2F452E3C-ABC4-4886-A69D-AC9AE36BC8F6

P433

Q33890039-C0AFA503-C29E-476E-8974-A74465717524

P478

Q33890039-C3E67B4B-7A75-46F5-BB69-ACECB67D4BCF

P50

Q33890039-D4CAE139-2D44-4D3F-A3F2-1471C73E936F

Q33890039-F34541F6-25AE-46CC-B9E4-CC423F77F6C5

P577

Q33890039-D9B92300-8678-40DF-B6E4-969469E8072C

P5875

Q33890039-E7C81318-6977-4B19-91B9-761780201244

P698

Q33890039-D8EAFDED-B815-4024-A7A5-A7E7B67A8227

P921

Q33890039-1C0D47B3-98AC-4F3A-A07C-FF69DAEE659D

P932

Q33890039-2BF222FF-FEEC-44F0-8EE1-4D7230E925D8

P356

P1433

Proteomics - Clinical Applications

P1476

Comparative proteomic analysis ...... trioid ovarian adenocarcinomas

@en

P2093

Dafydd G Thomas

http://www.w3.org/2001/XMLSchema#string

David E Misek

http://www.w3.org/2001/XMLSchema#string

David M Lubman

http://www.w3.org/2001/XMLSchema#string

Gabrielle Gossner

http://www.w3.org/2001/XMLSchema#string

Hyeyeung Kim

http://www.w3.org/2001/XMLSchema#string

J Rebecca Liu

http://www.w3.org/2001/XMLSchema#string

Kerby A Shedden

http://www.w3.org/2001/XMLSchema#string

Rong Wu

http://www.w3.org/2001/XMLSchema#string

P2860

D53 (TPD52L1) is a cell cycle-regulated protein maximally expressed at the G2-M transition in breast cancer cells

Wnt signaling and cancer

Inorganic pyrophosphate generation and disposition in pathophysiology

Interaction between tyrosine kinase Etk and a RUN domain- and FYVE domain-containing protein RUFY1. A possible role of ETK in regulation of vesicle trafficking

Cancer genes and the pathways they control

Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms

Cancer statistics, 2005

Tissue microarrays for high-throughput molecular profiling of tumor specimens

Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.

A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification.

P304

571-584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PRCA.200780004

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Giordano

P577

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44649756

http://www.w3.org/2001/XMLSchema#string

P698

20523764

http://www.w3.org/2001/XMLSchema#string

P921

P932

2879670

http://www.w3.org/2001/XMLSchema#string